Rate of neutropenic sepsis in relapsed NSCLC patients receiving docetaxel chemotherapy

被引：0
|
作者：
Gyi, M. M. [1 ]
Gulliford, T. J. [1 ]
Muthuramalingam, S. R. [1 ]
机构：
[1] Portsmouth Oncol Ctr, Oncol, Portsmouth, Hants, England
来源：
LUNG CANCER | 2017年 / 103卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
88
引用
收藏
页码：S41 / S42
页数：2
相关论文
共 50 条
  • [41] A validated risk model for early neutropenic events in older cancer patients receiving systemic chemotherapy
    Shayne, M.
    Culakova, E.
    Dale, D. C.
    Poniewierski, M. S.
    Wolff, D. A.
    Crawford, J.
    Lyman, H.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [42] Pharmacokinetics of oral posaconazole in neutropenic patients receiving chemotherapy for acute myelogenous leukemia or myelodysplastic syndrome
    Krishna, Gopal
    AbuTarif, Malaz
    Xuan, Fengjuan
    Martinho, Monika
    Angulo, David
    Cornely, Oliver A.
    PHARMACOTHERAPY, 2008, 28 (10): : 1223 - 1232
  • [43] LITHIUM-CARBONATE REDUCES EPISODES OF NEUTROPENIC INFECTION IN PATIENTS RECEIVING CHEMOTHERAPY FOR TESTICULAR CANCER
    TORTI, FM
    WOLIN, EM
    HANNIGAN, JF
    FREIHA, FS
    CLINICAL RESEARCH, 1984, 32 (02): : A423 - A423
  • [44] A risk model for first cycle neutropenic events in older cancer patients receiving systemic chemotherapy
    Shayne, M.
    Culakova, E.
    Poniewierski, M. S.
    Wolff, D. A.
    Crawford, J.
    Dale, D. C.
    Lyman, G. H.
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2006, 60 : S35 - S35
  • [45] Development of a risk prediction model for neutropenic complications in breast cancer patients receiving adjuvant chemotherapy
    Dranitsaris, G.
    Clemons, M.
    Verma, S.
    Vincent, M.
    BREAST, 2007, 16 : S41 - S42
  • [46] Risk of neutropenic complications in patients receiving systemic chemotherapy: Prospective risk model development.
    Crawford, J
    Dale, DC
    Wolff, D
    Agboola, O
    Culakova, E
    Lyman, GH
    BLOOD, 2003, 102 (11) : 168B - 169B
  • [47] Population pharmacokinetics of posaconazole in neutropenic patients receiving chemotherapy for acute myelogenous leukemia or myelodysplastic syndrome
    AbuTarif, M. A.
    Krishna, G.
    Statkevich, P.
    CURRENT MEDICAL RESEARCH AND OPINION, 2010, 26 (02) : 397 - 405
  • [48] Risk and Consequences of Neutropenic Complications Among Patients with Metastatic Solid Tumors Receiving Myelosuppressive Chemotherapy
    Weycker, Derek
    Li, Xiaoyan
    Kartashov, Alex
    Barron, Rich
    Edelsberg, John
    Xu, Hairong
    Girardi, Vincent
    Lyman, Gary H.
    BLOOD, 2013, 122 (21)
  • [49] THE IMPACT OF METFORMIN USE ON ONCOLOGIC OUTCOMES IN PROSTATE CANCER PATIENTS RECEIVING DOCETAXEL CHEMOTHERAPY
    Truong, Andrew
    Roberge, Gray
    Liou, Jinn-ing
    Abel, E. Jason
    Downs, Tracy
    Jarrard, David
    Richards, Kyle
    JOURNAL OF UROLOGY, 2018, 199 (04): : E1192 - E1192
  • [50] Phase II Study of Epirubicin in Combination With Weekly Docetaxel for Patients With Advanced NSCLC Who Have Failed or Relapsed After the Frontline Platinum-Based Chemotherapy
    Lin, Chih-Ming
    Chen, Chih-Hung
    Chang, John W. C.
    Tsao, Thomas C. Y.
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2009, 32 (02): : 169 - 173
12345